Atossa Genetics Inc. (ATOS): Price and Financial Metrics


Atossa Genetics Inc. (ATOS): $0.96

-0.05 (-5.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATOS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ATOS Stock Price Chart Interactive Chart >

Price chart for ATOS

ATOS Price/Volume Stats

Current price $0.96 52-week high $9.80
Prev. close $1.01 52-week low $0.88
Day low $0.94 Volume 1,366,400
Day high $1.02 Avg. volume 2,004,156
50-day MA $1.16 Dividend yield N/A
200-day MA $2.08 Market Cap 121.18M

Atossa Genetics Inc. (ATOS) Company Bio


Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.


ATOS Latest News Stream


Event/Time News Detail
Loading, please wait...

ATOS Latest Social Stream


Loading social stream, please wait...

View Full ATOS Social Stream

Latest ATOS News From Around the Web

Below are the latest news stories about Atossa Therapeutics Inc that investors may wish to consider to help them evaluate ATOS as an investment opportunity.

IceCure Medical, Atossa top healthcare gainers; Dermata, Statera among losers

IceCure Medical ICCM +16%. Atossa Therapeutics (ATOS) +15%. Dermata Therapeutics (DRMA) -31%. Statera Biopharma STAB -26%.

Seeking Alpha | February 7, 2022

The Olympics Business Model: Why Multi-Year Media Deals Matter

The Olympic Games have been a revenue generating enterprise for the IOC from nearly their inception. WSJ’s Stu Woo unpacks the history of brand partnerships and the challenges sponsors are facing at the Beijing Games. Photo: Fabrizio Bensch/Reuters

Yahoo | February 7, 2022

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today issued the following letter from President and CEO Dr. Steven C. Quay to Atossa stockholders: To Our Valued Stockholders: The last two years have changed the face of public health and uncovered t

Yahoo | January 27, 2022

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary DiseaseSEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces it is advancing to

Yahoo | January 18, 2022

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will be premenopausal women with elevated mammographic breast dens

Yahoo | December 22, 2021

Read More 'ATOS' Stories Here

ATOS Price Returns

1-mo -13.51%
3-mo -25.00%
6-mo -59.15%
1-year -69.91%
3-year -62.20%
5-year -84.91%
YTD -40.00%
2021 68.42%
2020 -39.49%
2019 53.92%
2018 -67.68%
2017 -81.35%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0097 seconds.